Cancers (Sep 2022)
Demographics, Outcomes, and Risk Factors for Patients with Sarcoma and COVID-19: A CCC19-Registry Based Retrospective Cohort Study
- Michael J. Wagner,
- Cassandra Hennessy,
- Alicia Beeghly,
- Benjamin French,
- Dimpy P. Shah,
- Sarah Croessmann,
- Diana Vilar-Compte,
- Erika Ruiz-Garcia,
- Matthew Ingham,
- Gary K. Schwartz,
- Corrie A. Painter,
- Rashmi Chugh,
- Leslie Fecher,
- Cathleen Park,
- Olga Zamulko,
- Jonathan C. Trent,
- Vivek Subbiah,
- Ali Raza Khaki,
- Lisa Tachiki,
- Elizabeth S. Nakasone,
- Elizabeth T. Loggers,
- Chris Labaki,
- Renee Maria Saliby,
- Rana R. McKay,
- Archana Ajmera,
- Elizabeth A. Griffiths,
- Igor Puzanov,
- William D. Tap,
- Clara Hwang,
- Sheela Tejwani,
- Sachin R. Jhawar,
- Brandon Hayes-Lattin,
- Elizabeth Wulff-Burchfield,
- Anup Kasi,
- Daniel Y. Reuben,
- Gayathri Nagaraj,
- Monika Joshi,
- Hyma Polimera,
- Amit A. Kulkarni,
- Khashayar Esfahani,
- Daniel H. Kwon,
- Luca Paoluzzi,
- Mehmet A. Bilen,
- Eric B. Durbin,
- Petros Grivas,
- Jeremy L. Warner,
- Elizabeth J. Davis
Affiliations
- Michael J. Wagner
- Department of Medicine, University of Washington, and Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA
- Cassandra Hennessy
- Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN 37232, USA
- Alicia Beeghly
- Department of Medicine, Division of Epidemiology, Vanderbilt University Medical Center, Nashville, TN 37232, USA
- Benjamin French
- Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN 37232, USA
- Dimpy P. Shah
- Department of Population Health Sciences, UT Health San Antonio, San Antonio, TX 78229, USA
- Sarah Croessmann
- Department of Medicine, Division of Hematology and Oncology, Vanderbilt University, Nashville, TN 37232, USA
- Diana Vilar-Compte
- Department of Infectious Diseases, Instituto Nacional de Cancerología, Mexico City 14080, Mexico
- Erika Ruiz-Garcia
- Department of Infectious Diseases, Instituto Nacional de Cancerología, Mexico City 14080, Mexico
- Matthew Ingham
- Department of Medicine, Columbia University Irving Medical Center, New York, NY 10032, USA
- Gary K. Schwartz
- Department of Medicine, Columbia University Irving Medical Center, New York, NY 10032, USA
- Corrie A. Painter
- Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA
- Rashmi Chugh
- Department of Hematology and Oncology, University of Michigan, Ann Arbor, MI 48109, USA
- Leslie Fecher
- Department of Hematology and Oncology, University of Michigan, Ann Arbor, MI 48109, USA
- Cathleen Park
- University of Cincinnati Cancer Center, Cincinnati, OH 45267, USA
- Olga Zamulko
- University of Cincinnati Cancer Center, Cincinnati, OH 45267, USA
- Jonathan C. Trent
- Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL 33136, USA
- Vivek Subbiah
- Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
- Ali Raza Khaki
- Department of Medicine, Stanford University, Stanford, CA 94304, USA
- Lisa Tachiki
- Department of Medicine, University of Washington, and Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA
- Elizabeth S. Nakasone
- Department of Medicine, University of Washington, and Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA
- Elizabeth T. Loggers
- Department of Medicine, University of Washington, and Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA
- Chris Labaki
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA
- Renee Maria Saliby
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA
- Rana R. McKay
- Department of Medicine, Moores Cancer Center, University of California San Diego, San Diego, CA 92037, USA
- Archana Ajmera
- Department of Medicine, Moores Cancer Center, University of California San Diego, San Diego, CA 92037, USA
- Elizabeth A. Griffiths
- Department of Medicine, Roswell Park Comprehensive Cancer Center, University of Buffalo, Buffalo, NY 14203, USA
- Igor Puzanov
- Department of Medicine, Roswell Park Comprehensive Cancer Center, University of Buffalo, Buffalo, NY 14203, USA
- William D. Tap
- Department of Medical Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA
- Clara Hwang
- Henry Ford Cancer Institute, Detroit, MI 48202, USA
- Sheela Tejwani
- Henry Ford Cancer Institute, Detroit, MI 48202, USA
- Sachin R. Jhawar
- Department of Radiation Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA
- Brandon Hayes-Lattin
- Division of Hematology and Medical Oncology, Knight Cancer Institute at Oregon Health and Science University, Portland, OR 97239, USA
- Elizabeth Wulff-Burchfield
- Department of Medicine, The University of Kansas Medical Center, Kansas City, KS 66103, USA
- Anup Kasi
- Department of Medicine, The University of Kansas Medical Center, Kansas City, KS 66103, USA
- Daniel Y. Reuben
- Hollings Cancer Center, Medical University of South Carolina, Charleston, SC 29425, USA
- Gayathri Nagaraj
- Division of Hematology and Oncology, Loma Linda University School of Medicine, California, CA 92354, USA
- Monika Joshi
- Department of Medicine, Division of Hematology-Oncology, Penn State Cancer Institute, Hershey, PA 17033, USA
- Hyma Polimera
- Department of Medicine, Division of Hematology-Oncology, Penn State Cancer Institute, Hershey, PA 17033, USA
- Amit A. Kulkarni
- Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA
- Khashayar Esfahani
- Segal Cancer Centre, Jewish General Hospital, McGill University, Montreal, QC H4A 3J1, Canada
- Daniel H. Kwon
- UCSF Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, California, CA 94117, USA
- Luca Paoluzzi
- Department of Oncology, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY 10467, USA
- Mehmet A. Bilen
- Department of Oncology, Emory University, Atlanta, GA 30322, USA
- Eric B. Durbin
- Division of Biomedical Informatics, College of Medicine, University of Kentucky, Lexington, KY 40536, USA
- Petros Grivas
- Department of Medicine, University of Washington, and Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA
- Jeremy L. Warner
- Department of Medicine, Division of Hematology and Oncology, Vanderbilt University, Nashville, TN 37232, USA
- Elizabeth J. Davis
- Department of Medicine, Division of Hematology and Oncology, Vanderbilt University, Nashville, TN 37232, USA
- DOI
- https://doi.org/10.3390/cancers14174334
- Journal volume & issue
-
Vol. 14,
no. 17
p. 4334
Abstract
Background: Patients with sarcoma often require individualized treatment strategies and are likely to receive aggressive immunosuppressive therapies, which may place them at higher risk for severe COVID-19. We aimed to describe demographics, risk factors, and outcomes for patients with sarcoma and COVID-19. Methods: We performed a retrospective cohort study of patients with sarcoma and COVID-19 reported to the COVID-19 and Cancer Consortium (CCC19) registry (NCT04354701) from 17 March 2020 to 30 September 2021. Demographics, sarcoma histologic type, treatments, and COVID-19 outcomes were analyzed. Results: of 281 patients, 49% (n = 139) were hospitalized, 33% (n = 93) received supplemental oxygen, 11% (n = 31) were admitted to the ICU, and 6% (n = 16) received mechanical ventilation. A total of 23 (8%) died within 30 days of COVID-19 diagnosis and 44 (16%) died overall at the time of analysis. When evaluated by sarcoma subtype, patients with bone sarcoma and COVID-19 had a higher mortality rate than patients from a matched SEER cohort (13.5% vs 4.4%). Older age, poor performance status, recent systemic anti-cancer therapy, and lung metastases all contributed to higher COVID-19 severity. Conclusions: Patients with sarcoma have high rates of severe COVID-19 and those with bone sarcoma may have the greatest risk of death.
Keywords
